Rethinking the role of osteopontin in human acute myeloid leukemia

Leukemia and Lymphoma

Volumn 58, Issue 6, 2017, Pages 1494-1497

  Brenner, Annette K ^a   Aasebø, Elise ^a   Hernandez Valladares, Maria ^a   Selheim, Frode ^a   Berven, Frode ^a   Bruserud, Øystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN RELATED PROTEIN 2-3 COMPLEX; ANTHRACYCLINE; ATPASE HYDROGEN TRANSPORTING ACCESSORY PROTEIN; BETA GLUCURONIDASE; CALNEXIN; CARBOXYPEPTIDASE C; CARTILAGE ASSOCIATED PROTEIN; CD135 ANTIGEN; CD34 ANTIGEN; COLLAGEN BETA(1 O)GALACTOSYLTRANSFERASE; CYTARABINE; FLOTILLIN 2; GALACTOKINASE; GALACTOSYLTRANSFERASE; LYSYL OXIDASE LIKE 3; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; NUCLEOPHOSMIN; OSTEOPONTIN; OXIDOREDUCTASE; PALMITOYL PROTEIN THIOESTERASE; PALMITOYL PROTEIN THIOESTERASE 1; PROCOLLAGEN LYSINE 2 OXOGLUTARATE 5 DIOXYGENASE 3; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; SULFATASE MODIFYING FACTOR 1 PROTEIN; SULFOTRANSFERASE FAMILY 1A MEMBER 3 PROTEIN; SULFOTRANSFERASE FAMILY 1A MEMBER 4 PROTEIN; THIOREDOXIN REDUCTASE 2; TUMOR MARKER; UBIQUITIN LIKE 4 A PROTEIN; UNCLASSIFIED DRUG;

ACUTE MYELOID LEUKEMIA; ADULT; AGE; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; INDUCTION CHEMOTHERAPY; LETTER; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN SECRETION; SERUM-FREE MEDIUM; SINGLE DRUG DOSE; SURVIVAL ANALYSIS; ADOLESCENT; CELL CULTURE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; PROGNOSIS; RECURRENT DISEASE; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CELLS, CULTURED; COMBINED MODALITY THERAPY; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; OSTEOPONTIN; PROGNOSIS; RECURRENCE; YOUNG ADULT;

EID: 84991032506     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428194.2016.1243682     Document Type: Letter

References (12)

1. Lee CY, Tien HF, Hou HA, et al. Marrow osteopontin level as a prognostic factor in acute myeloid leukaemia. Br J Haematol. 2008;141:736–739.
2. Liersch R, Gerss J, Schliemann C, et al. Osteopontin is a prognostic factor for survival of acute myeloid leukemia patients. Blood. 2012;119:5215–5220.
3. Powell JA, Thomas D, Barry EF, et al. Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood. 2009; 114:4859–4870.
4. Bruserud Ø, Ryningen A, Olsnes AM, et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 2007;92:332–341.
5. Reikvam H, Brenner AK, Hagen KM, et al. The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. Stem Cell Res. 2015;15:530–541.
6. Hatfield KJ, Hovland R, Øyan AM, et al. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia. 2008;22:287–293.
7. Reikvam H, Tamburini J, Skrede S, et al. Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. Br J Haematol. 2014;164:200–211.
8. Aasebø E, Mjaavatten O, Vaudel M, et al. Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows. J Proteomics. 2016;145:214–225.
9. Zhang R, Yang W, Li YC, et al. The OPN gene polymorphism confers the susceptibility and response to Ara-C based chemotherapy in Chinese AML patients. Cell Physiol Biochem. 2015; 35:175–183.
10. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults:recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474.
11. Bruserud Ø, Hovland R, Wergeland L, et al. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts:a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica. 2003;88:416–428.
12. Hatfield KJ, Evensen L, Reikvam H, et al. Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks. Eur J Haematol. 2012;89:478–490.